Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

Cristina Royo-Cebrecos 1, Julia Laporte-Amargós 2,3,4, Marta Peña 4, Isabel Ruiz-Camps 5, Pedro Puerta-Alcalde 6, Edson Abdala 7, Chiara Oltolini 8, Murat Akova 9, Miguel Montejo 10, Malgorzata Mikulski 11, Pilar Martin-Dávila 12, Fabian Herrera 13, Oriol Gasch 14, Lubos Drgona 15, Hugo Manuel Paz Morales 16, Anne-Sophie Brunel 17, Estefanía García 18, Burcu Isler 19, Winfried V. Kern 20, Zaira R. Palacios-Baena 21, Guillermo Maestro de la Calle 22, María Milagro Montero 23, Souha S. Kanj 24, Oguz R. Sipahi 25, Sebnem Calik 26, Ignacio Márquez-Gómez 27, Jorge I. Marin 28, Marisa Z. R. Gomes 29, Philipp Hemmatti 30, Rafael Araos 31, Maddalena Peghin 32, José Luis del Pozo 33, Lucrecia Yáñez 34, Robert Tilley 35, Adriana Manzur 36, Andrés Novo 37, Jordi Carratalà 2,3,9, and Carlota Gudiol 2,3,38,39,† on behalf of the IRONIC study group

1 Internal Medicine Department, Hospital Nostra Senyora de Meritxell, Andorra Health Services (SAAS), AD700 Escaldes-Engordany, Andorra
2 Infectious Diseases Department, Bellvitte University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain
3 Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, 08907 Barcelona, Spain
4 Hematology Department, Institut Català d’Oncologia (ICO)—Hospital Duran i Reynals, IDIBELL, 08907 Barcelona, Spain
5 Infectious Diseases Department, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
6 Infectious Diseases Department, Hospital Clinic i Provincial, 08035 Barcelona, Spain
7 Instituto de Câncer do Estado de São Paulo, Faculty of Medicine, University of São Paulo, São Paulo 01246, Brazil
8 Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
9 Department of Infectious Diseases, Facultetepe University School of Medicine, 06230 Ankara, Turkey
10 Infectious Diseases Unit, Cruces University Hospital, 48903 Bilbao, Spain
11 Division of Infectious Diseases, University of Genoa (DISAB) and Ospedale Policlinico San Martino, 16132 Genoa, Italy
12 Infectious Diseases Department, Ramon y Cajal Hospital, 28034 Madrid, Spain
13 Infectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires C1430EFA, Argentina
14 Infectious Diseases Department, Parc Taulí University Hospital, 08208 Sabadell, Spain
15 Oncohematology Department, Comenius University and National Cancer Institute, 81499 Bratislava, Slovakia
16 Infectious Diseases Department, Hospital Erasto Gaertner, Curitiba 81520-060, Brazil
17 Infectious Diseases Department, Department of Medicine, Lausanne University Hospital, (CHUV), 1011 Lausanne, Switzerland
18 Hematology Department, Reina Sofia University Hospital-IMIBIC-UCO, Córdoba 14004, Argentina
19 Department of Infectious Diseases and Clinical Microbiology, Istanbul Education and Research Hospital, 34668 Istanbul, Turkey
20 Division of Infectious Diseases, Department of Medicine II, University of Freiburg Medical Center and Faculty of Medicine, 79106 Freiburg, Germany
21 Unit of Infectious Diseases and Clinical Microbiology, Virgen Macarena University Hospital, Institute of Biomedicine of Seville (IBIS), 41013 Sevilla, Spain
22 Infectious Diseases Unit, Instituto de Investigación Hospital “12 de Octubre” (i+12), “12 de Octubre”, University Hospital, School of Medicine, Universidad Complutense, 28041 Madrid, Spain
23 Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain
24 Infectious Diseases Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
25 Faculty of Medicine, Ege University, 35040 Izmir, Turkey
26 University of Health Science Izmir Bozyaka Training and Research Hospital, 35170 Izmir, Turkey
27 Infectious Diseases Department, Hospital Regional de Málaga, 29010 Málaga, Spain
28 Infectious Diseases and Clinical Microbiology Department, Clínica Maraya, Pereira, Colombia. Critical Care and Clinical Microbiology Department, Manizales 170001-17, Colombia

Pathogens 2022, 11, 1132. https://doi.org/10.3390/pathogens11101132

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Abstract: Objectives: To assess the clinical features and outcomes of *Pseudomonas aeruginosa* bloodstream infection (PA BSI) in neutropenic patients with hematological malignancies (HM) and with solid tumors (ST), and identify the risk factors for 30-day mortality. Methods: We performed a large multicenter, retrospective cohort study including onco-hematological neutropenic patients with PA BSI conducted across 34 centers in 12 countries (January 2006–May 2018). Episodes occurring in hematologic patients were compared to those developing in patients with ST. Risk factors associated with 30-day mortality were investigated in both groups. Results: Of 1217 episodes of PA BSI, 917 occurred in patients with HM and 300 in patients with ST. Hematological patients had more commonly profound neutropenia (0.1 $\times$ $10^9$ cells/mm) (67% vs. 44.6%; $p < 0.001$), and a high risk Multinational Association for Supportive Care in Cancer (MASCC) index score (32.2% vs. 26.7%; $p = 0.05$). Catheter-infection (10.7% vs. 4.7%; $p = 0.001$), mucositis (2.4% vs. 0.7%; $p = 0.042$), and perianal infection (3.6% vs. 0.3%; $p = 0.001$) predominated as BSI sources in the hematological patients, whereas pneumonia (22.9% vs. 33.7%; $p < 0.001$) and other abdominal sites (2.8% vs. 6.3%; $p = 0.006$) were more common in patients with ST. Hematological patients had more frequent BSI due to multidrug-resistant *P. aeruginosa* (MDRPA) (23.2% vs. 7.7%; $p < 0.001$), and were more likely to receive inadequate initial antibiotic therapy (IEAT) (20.1% vs. 12%; $p < 0.001$). Patients with ST presented more frequently with septic shock (45.8% vs. 30%; $p < 0.001$), and presented worse outcomes, with increased 7-day (38% vs. 24.2%; $p < 0.001$) and 30-day (49% vs. 37.3%; $p < 0.001$) case-fatality rates. Risk factors for 30-day mortality in hematologic patients were high risk MASCC index score, IEAT, pneumonia, infection due to MDRPA, and septic shock. Risk factors for 30-day mortality in patients with ST were high risk MASCC index score, IEAT, persistent BSI, and septic shock. Therapy with granulocyte colony-stimulating factor was associated with survival in both groups. Conclusions: The clinical features and outcomes of PA BSI in neutropenic cancer patients showed some differences depending on the underlying malignancy. Considering these differences and the risk factors for mortality may be useful to optimize their therapeutic management. Among the risk factors associated with overall mortality, IEAT and the administration of granulocyte colony-stimulating factor were the only modifiable variables.

Keywords: *Pseudomonas aeruginosa*; bacteremia; bloodstream infection; cancer; solid tumor; hematologic malignancy
1. Introduction

Bloodstream infection (BSI) is a major cause of morbidity and mortality in neutropenic cancer patients. A shift in the etiology of BSI to Gram-negative bacilli (GNB) as well as an increase in antibiotic resistance among them have been reported in cancer patients in the last decades [1–4]. *Pseudomonas aeruginosa* (PA) has historically been one of the major causes of severe sepsis and high mortality in cancer patients with neutropenia [5–8]. Thus, the emergence of antimicrobial resistance in PA is of special concern, since initial inadequate empirical antibiotic therapy (IEAT) is associated with increased mortality in this setting [9–12].

We recently published the results of a large international cohort study (the IRONIC study) in which we found a significant increase in BSI due to multidrug-resistant PA (MDRPA) in neutropenic cancer patients throughout the study period (2006–2018) [13]. In this study, we provided a predictive model for multidrug resistance that can be easily calculated using a web-based calculator (Risk of Multidrug resistance *Pseudomonas aeruginosa Bloodstream Infection* (MDR-PA BSI). Available online: http://ubidi.shinyapps.io/ironic, accessed on 20 July 2022) and allows for the identification of the patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns. The cohort of patients consisted of patients with hematologic malignancies (HM) including hematopoietic stem cell transplant (HSCT) recipients, along with patients with solid tumors (ST). Patients with HM and with ST are often considered as a single group of patients when it comes to providing recommendations on the management of febrile neutropenia [14,15]. Nevertheless, these two groups of patients present significant differences in the etiology, clinical presentation, and outcomes of BSI during neutropenia [16]. In fact, the risk factors associated with mortality in patients with BSI also appear to be different, depending on the underlying malignant condition [17].

The available literature on *Pseudomonas aeruginosa* bloodstream infection (PA BSI) usually focuses on hematologic patients [6–8,11,18], and there is no available information specifically on patients with ST, who indeed, appeared to be more susceptible to PA BSI than the hematologic patients in the above-mentioned study [13]. The knowledge of the potential differences between patients with HM and ST presenting with PA BSI could be useful in order to improve their management during febrile neutropenia. Thus, the aim of this study was to identify the differences in the clinical presentation, rates of multidrug resistance, source of infection, outcomes, and risk factors for the 30-day mortality of BSI due to PA in patients with HM compared to patients with ST, analyzing the large cohort of neutropenic patients with PA BSI (the IRONIC cohort).

2. Material and Methods

2.1. Study Design and Setting

This study is part of the IRONIC project: a large multicenter, international, retrospective cohort study conducted from 1 January 2006 to 31 May 2018 at 34 centers in 12 countries. The number of participating centers and the number of patients recruited at each one has previously been published (IRONIC) [13].

2.2. Participants

All adult (≥18 years) onco-hematological neutropenic patients including hematopoietic stem cell transplant (HSCT) recipients were eligible for the study if they were diagnosed with at least one episode of PA BSI during the study period. Subsequent episodes caused by PA occurring in the same patient were included in the study if they occurred at intervals of more than one month. The follow-up period was 30 days from BSI onset.

2.3. Variables

Data regarding the baseline characteristics, clinical and microbiological features, and the endpoints were collected. Empirical antibiotic therapy was considered when the antibiotic was administered before the reception of definitive susceptibility results. Adequate
initial empirical antibiotic therapy was defined when patients received at least one in vitro active antibiotic against the PA strain. Initial IEAT was considered when the patient did not receive any empirical antibiotic with in vitro activity, or an empirical antibiotic therapy was lacking. The antipseudomonal β-lactams were uniformly administered at the current standard doses for the treatment of febrile neutropenia [14,15]. In the case of renal impairment, the dosing was adjusted accordingly.

2.4. Outcomes

Episodes of PA BSI occurring in HM patients were compared to those developing in patients with ST. Risk factors associated with 30-day mortality were investigated in both groups.

2.5. Microbiological Studies

Clinical samples were processed at the microbiology laboratories of each participating center in accordance with the standard operating procedures. PA was identified using standard microbiological techniques at each center. In vitro susceptibility was determined according to the EUCAST recommendations [19], except at a center in Lebanon and at one center in Argentina, where the CLSI break points were used, and at the center in the UK where the BSAC recommendations were used before 2016 [20]. PA isolate phenotypes were stratified in accordance with recent standard definitions; multidrug-resistant (MDR) was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories; extensively drug-resistant (XDR) was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories, as previously described [21].

2.6. Definitions

Neutropenia and profound neutropenia were defined as an absolute neutrophil count below $0.5 \times 10^9$ cells/mm and $0.1 \times 10^9$ cells/mm, respectively [14]. The Multinational Association for Supportive Care in Cancer (MASCC) score was calculated as described elsewhere [22]. Previous corticosteroid treatment was defined as the administration of ≥20 mg of prednisone, or equivalent dosing, for at least four weeks within 30 days of BSI onset. Bacteremic PA pneumonia was defined as the presence of an acute respiratory illness and a new pulmonary infiltrate on a chest radiograph and/or chest tomography in association with concurrent PA BSI.

Other BSI sources were established using standard U.S. Centers for Disease Control and Prevention criteria for secondary BSI [23]. In addition, the source of BSI was defined as unknown or endogenous in patients in whom no other sources were identified. Septic shock was defined as a systolic blood pressure <90 mmHg that was unresponsive to fluid treatment or required vasoactive drug therapy [24]. Mucositis was considered in patients with ulcerative lesions involving only the oral cavity. Comorbidities were defined as the presence of one or more of the following diseases: chronic obstructive pulmonary disease (COPD), chronic heart disease, chronic hepatic disease, diabetes mellitus, chronic renal disease, and cerebrovascular disease.

Persistent BSI was considered if the blood cultures were positive after 48 h of adequate antibiotic therapy. The 7-day and 30-day case-fatality rates were defined as death from any cause within 7 days and 30 days of BSI onset, respectively.

2.7. Statistical Analysis

To define the cohort characteristics, categorical variables were presented as the number of cases and percentages, while continuous variables were presented as the mean and standard deviation (SD) or median and interquartile range (IQR). Continuous variables were compared using the Student’s t-test or the Mann–Whitney U test where appropriate. Fisher’s exact test or Pearson’s χ² test were applied to assess the relationship between categorical variables. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A p value of <0.05 was considered statistically significant. The analysis was performed with
the stepwise logistic-regression model of the SPSS software package version 19.0 (SPSS Inc., Chicago, IL, USA).

2.8. Ethics

The study was approved by the Institutional Review Board at Bellvitge University Hospital (local reference number PR408/17) and by the local Research Ethics Committees at the participating centers. It was conducted in accordance with the guidelines of the Declaration of Helsinki. The need for informed consent was waived by the Clinical Research Ethics Committee due to the retrospective design.

3. Results

3.1. Clinical Characteristics

Of the 1217 episodes of PA BSI, 917 occurred in patients with HM and 300 in patients with ST. In hematological patients, the most frequent malignancies were acute leukemia 312 (34%), non-Hodgkin lymphoma 271 (29.6%), and acute lymphoblastic leukemia 97 (10.6%), and among them, 289 (31.5%) received a hematopoietic stem cell transplant. The most common malignancies among patients with solid tumors were lung cancer 89 (29.7%), lower gastrointestinal cancer 30 (10%), urinary cancer 29 (9.7%), breast cancer 28 (9.3%) and head and neck cancer 26 (8.7%). Baseline characteristics of the patients included in the study are detailed in Table 1. Patients with HM were significantly younger, had more frequent profound neutropenia, a higher MASCC index score and severe mucositis. They also more often received previous biological therapies, corticosteroids, and antibiotics. Patients with ST were more likely to have comorbidities than patients with HM, especially COPD, and had received more frequent previous chemotherapy. Catheter-related infection, mucositis, and perineal infection were more common in patients with HM, whereas pneumonia and other abdominal sources were more frequent in ST patients.

Table 1. The epidemiological and clinical characteristics of episodes of *Pseudomonas aeruginosa* bloodstream infection in patients with hematological malignancies and solid tumors.

| Characteristics                             | Overall n = 1217 | Hematological Malignancies n = 917 (%) | Solid Tumors n = 300 (%) | p-Value |
|---------------------------------------------|-----------------|---------------------------------------|--------------------------|---------|
| Age (years, median, range)                  | 60 (IQR 20)     | 59 (IQR 21)                           | 64 (IQR 17)              | <0.001  |
| Male sex                                    | 751             | 559 (61.0)                            | 192 (64.0)               | 0.192   |
| Comorbidities                               | 586             | 426 (48.4)                            | 160 (57.1)               | 0.007   |
| Chronic heart disease                       | 149             | 120 (13.1)                            | 29 (9.7)                 | 0.069   |
| Chronic obstructive pulmonary disease       | 100             | 54 (5.9)                              | 46 (15.3)                | <0.001  |
| Diabetes mellitus                           | 86              | 60 (6.5)                              | 26 (8.7)                 | 0.144   |
| Chronic liver disease                       | 68              | 52 (5.7)                              | 16 (5.3)                 | 0.478   |
| Other comorbidities *                       | 183             | 140 (15.3)                            | 43 (14.3)                | 0.386   |
| High risk MASCC * index score               | 341             | 269 (32.2)                            | 72 (26.7)                | 0.050   |
| Profound neutropenia (0.1 × 10⁹ cells/mm)  | 728             | 600 (67.0)                            | 128 (44.6)               | <0.001  |
| Previous chemotherapy (1 month)             | 1037            | 764 (83.6)                            | 273 (91.3)               | <0.001  |
| Previous biological therapies (3 months)    | 186             | 172 (19.2)                            | 14 (4.8)                 | <0.001  |
Table 1. Cont.

| Characteristics                        | Overall n = 1217 | Hematological Malignancies n = 917 (%) | Solid Tumors n = 300 (%) | p-Value |
|----------------------------------------|-----------------|---------------------------------------|--------------------------|---------|
| Previous hospital admission (3 months) | 744             | 574 (63.1)                            | 170 (57.8)               | 0.062   |
| Severe mucositis (grade III-IV)        | 169             | 142 (15.7)                            | 27 (9.1)                 | 0.002   |
| Corticosteroid therapy (1 month)       | 832             | 727 (58.3)                            | 105 (36.4)               | <0.001  |
| Previous antibiotic therapy (1 month)  | 665             | 591 (65.4)                            | 74 (25.3)                | <0.001  |
| Prior quinolone prophylaxis            | 195             | 186 (20.5)                            | 9 (3.0)                  | <0.001  |
| Intravenous vascular catheter          | 908             | 756 (82.5)                            | 152 (50.7)               | <0.001  |
| Urinary catheter                       | 206             | 162 (18.1)                            | 44 (15.1)                | 0.132   |
| Nosocomial acquisition                 | 694             | 620 (67.6)                            | 74 (24.7)                | <0.001  |
| Source of bloodstream infection        |                 |                                       |                          |         |
| Endogenous source                     | 751             | 348 (37.9)                            | 107 (35.7)               | 0.261   |
| Pneumonia                              | 586             | 210 (22.9)                            | 101 (33.7)               | <0.001  |
| Urinary tract                          | 311             | 34 (3.7)                              | 17 (5.7)                 | 0.099   |
| Catheter-related infection             | 112             | 98 (10.7)                             | 14 (4.7)                 | 0.001   |
| Other abdominal *                      | 112             | 26 (2.8)                              | 19 (6.3)                 | 0.006   |
| Neutropenic enterocolitis              | 71              | 57 (6.2)                              | 14 (4.7)                 | 0.199   |
| Mucositis                              | 71              | 22 (2.4)                              | 2 (0.7)                  | 0.042   |
| Skin and soft tissue infection         | 70              | 57 (6.2)                              | 13 (4.3)                 | 0.141   |
| Unknown origin                         | 70              | 13 (1.4)                              | 2 (0.7)                  | 0.244   |
| Perineal infection                     | 51              | 3 (3.6)                               | 1 (0.3)                  | 0.001   |
| Septic shock at presentation           | 411             | 274 (30.0)                            | 137 (45.8)               | <0.001  |
| Septic metastases                     | 88              | 78 (8.9)                              | 10 (3.4)                 | <0.001  |
| Gangrenous ecthyma                     | 51              | 50 (5.5)                              | 1 (0.3)                  | <0.001  |

* Other comorbidities included chronic renal disease and cerebrovascular disease. MASCC (Multinational Association for Supportive Care in Cancer). Other abdominal sources included cholangitis, peritonitis, and intraabdominal abscesses.

3.2. Etiology and Antibiotic Resistance

Hematological patients frequently had more BSI due to MDRPA (23.2% vs. 7.7%; p < 0.001) and XDRPA (17.2% vs. 5.3%; p < 0.001). The rate of polymicrobial infection did not differ between groups (17.9% vs. 17.7%).

3.3. Empirical Antibiotic Therapy and Clinical Outcomes

Empirical antibiotic therapy and clinical outcomes are described in Table 2. Patients with ST frequently received more monotherapy (73.6% vs. 57.5%; p < 0.001) whereas patients with HM were more likely to receive IEAT (20.1% vs. 12%; p < 0.001). Patients with ST presented more frequently with septic shock (45.8% vs. 30%; p < 0.001), and also presented worse outcomes, with increased 7-day (38% vs. 24.2%; p < 0.001) and 30-day (49% vs. 37.3%; p < 0.001) case-fatality rates.
Table 2. The empirical antibiotic therapy and clinical outcomes of *Pseudomonas aeruginosa* bloodstream infection compared by groups.

| Characteristics                                      | Hematological Malignancies | Solid Tumors | p-Value |
|------------------------------------------------------|-----------------------------|--------------|---------|
| **Empirical Antibiotic Therapy**                     |                             |              |         |
| Monotherapy                                          | 519 (57.5)                  | 218 (73.6)   | 0.000   |
| Combination therapy                                  | 383 (42.5)                  | 78 (26.4)    | <0.001  |
| β-lactam + aminoglycoside                            | 209 (23.2)                  | 51 (17.2)    | 0.031   |
| β-lactam + non-aminoglycoside                        | 55 (6.1)                    | 17 (5.7)     | 0.821   |
| Initial inadequate empirical antibiotic therapy       | 184 (20.1)                  | 36 (12.0)    | <0.001  |
| Carbapenems                                          | 89                          | 10           |         |
| Piperacillin-tazobactam                              | 52                          | 13           |         |
| Glycopeptides                                        | 35                          | 7            |         |
| Aminoglycosides                                      | 18                          | 1            |         |
| Broad-spectrum cephalosporins                        | 15                          | 1            |         |
| Quinolones                                           | 11                          | 1            |         |
| Other                                                | 42                          | 17           |         |
| Granulocyte colony-stimulating factor                | 490 (54)                    | 136 (45.9)   | 0.009   |
| **Clinical Outcomes**                                |                             |              |         |
| Intensive care unit admission                        | 285 (31.1)                  | 103 (34.3)   | 0.164   |
| Invasive mechanical ventilation                      | 187 (20.4)                  | 59 (19.7)    | 0.422   |
| Persistent bloodstream infection                     | 111 (12.3)                  | 23 (7.9)     | 0.024   |
| Early case-fatality rate (7 days)                    | 222 (24.2)                  | 114 (38.0)   | <0.001  |
| Overall case-fatality rate (30 days)                 | 342 (37.3)                  | 147 (49.0)   | <0.001  |

3.4. Risk Factors for Overall Case-Fatality Rate

Risk factors for 30-day mortality are described in Tables 3 and 4. High risk MASCC index score, IEAT, pneumonia, infection due to MDRPA and septic shock were associated with 30-day case fatality rate in hematologic patients (Table 3). A high risk MASCC index score, IEAT, persistent BSI, and septic shock were associated with the 30-day case fatality rate in patients with ST (Table 4). Therapy with the granulocyte colony-stimulating factor was associated with survival in both groups.

Table 3. The risk factors for the overall case-fatality rate in hematological patients by univariate and multivariate analysis.

| Characteristics                                      | n     | Adjusted OR (95% CI) | p-Value |
|------------------------------------------------------|-------|----------------------|---------|
| Age                                                  | 1.01  | (0.99–1.02)          | 0.088   |
| Male sex                                             | 559 (61.0) | 0.74 (0.51–1.08) | 0.126   |
| High risk MASCC index score                          | 269 (32.2) | 2.53 (1.63–3.95) | <0.001  |
| Initial inadequate empirical antibiotic therapy       | 184 (20.1) | 3.45 (1.09–10.92) | <0.035  |
| Persistent bloodstream infection                     | 111 (12.3) | 1.43 (0.83–2.47) | 0.195   |
| Granulocyte colony-stimulating factor                | 490 (54)  | 0.53 (0.36–0.76) | 0.001   |
| Pneumonia                                            | 210 (22.9) | 2.23 (1.47–3.38) | <0.001  |
| MDRPA                                                | 157 (17.2) | 2.22 (1.44–3.41) | <0.001  |
| Septic shock                                         | 274 (30.0) | 7.12 (4.78–10.60) | <0.001  |

MDRPA: Multidrug-resistant *Pseudomonas aeruginosa*. 
Table 4. The risk factors for the overall case-fatality rate in patients with solid tumors by univariate and multivariate analysis.

| Characteristics                      | n     | Adjusted OR (95% CI) | p-Value |
|--------------------------------------|-------|----------------------|---------|
| Age                                  | 1.01  | (0.98–1.03)          | 0.329   |
| Male sex                             | 0.98  | (0.52–1.83)          | 0.949   |
| High risk MASCC index score          | 2.68  | (1.21–5.94)          | 0.015   |
| Inadequate initial empirical antibiotic therapy | 2.84  | (1.10–7.35)          | 0.031   |
| Persistent bloodstream infection     | 9.92  | (2.08–47.20)         | 0.004   |
| Granulocyte colony-stimulating factor| 0.26  | (0.14–0.48)          | <0.001  |
| Septic shock                         | 3.97  | (2.10–7.51)          | <0.001  |

3.5. Discussion

This large, multicenter, international cohort study of high-risk neutropenic cancer patients identified several differences between hematological patients and those with solid tumors with PA BSI that can be useful to optimize their therapeutic management. Hematological patients frequently had more profound neutropenia and BSI from an endogenous source and from the catheter, and were more likely to receive IEAT due to higher rates of multidrug resistance among the PA isolates. Conversely, patients with solid tumors frequently had more COPD and pneumonia, and presented poorer outcomes, with higher rates of septic shock at presentation and higher case-fatality rates.

Of note, pneumonia was the second cause of PA BSI in both groups of patients, but it was significantly more frequent in patients with solid tumors. This is probably due to the fact that the latter group of patients often had COPD as a relevant comorbidity and lung cancer as the underlying disease. The presence of dysfunctional malignant cells in the lung tissue predisposes to invasive disease in these patients, who are often colonized by *Pseudomonas aeruginosa* [25]. In contrast, PA BSI in hematological patients was mainly associated with the administration of myeloablative chemotherapy and its consequences such as the presence of profound neutropenia and mucositis and the infection of long-term central venous catheters. Even though Gram-positives still remain the leading cause of catheter-related BSI, an increase in Gram-negatives has been described in the last decades [26–28].

An important finding of our study is that hematological patients frequently had more infections due to MDRPA and XDRPA and were more likely to receive IEAT. This is probably a consequence of the increased rates of previous antibiotic exposure in this group of patients as well as the use of quinolone prophylaxis [1,29,30]. Even though the reduction of antibiotic consumption is one of the major cornerstones in the fight against antibacterial resistance, this strategy may be difficult to accomplish in these high-risk patients. Nevertheless, in light of numerous studies that have identified the use of quinolone prophylaxis as a major risk factor for multidrug resistance, the universal use of this preventive strategy is no longer recommended, particularly when the rates of quinolone resistance among Gram-negatives are high in some centers [13,31,32].

Importantly, carbapenems and piperacillin-tazobactam were the most common inadequate empirical agents used in both groups. This finding is of special concern in the current era of widespread antimicrobial resistance and emerging resistance to carbapenems. Thus, the administration of combined empirical therapy and the prompt use of the recently available antibiotics in febrile cancer patients should be seriously considered [33–37].

As observed in other series of hematological patients with PA BSI, the early and overall case-fatality rates of the whole cohort were high [6,8–12]. Of note, outcomes were better in patients with hematological malignancies in spite of more frequently presenting persistent BSI and receiving IEAT more often. One plausible explanation is that solid tumor patients...
were older, with more comorbidities, more frequent advanced neoplasm, more septic shock at presentation, and pneumonia as the source of BSI.

Finally, a high MASCC index score, septic shock, and IEAT were all identified as risk factors for 30-day case fatality rates in both groups, whereas receiving therapy with granulocyte colony-stimulating factor (G-CSF) was associated with improved survival. It is noteworthy that the improvement in the empirical treatment and the administration of G-CSF were the only modifiable factors associated with mortality in our study.

The main strength of this study is that it is based on one of the largest cohorts of neutropenic cancer patients with PA BSI, with a multicenter international design that allows for generalization of the results. Nevertheless, this study also has some limitations that should be acknowledged. First, this is a retrospective study, so the main limitation of the data is related to the potential effects of unmeasured variables and residual confounding. Second, this was not a randomized clinical trial; thus, the choice of therapy may have been influenced by patient-related variables and by the clinical presentation. Finally, it was a relatively long period, and it is not possible to rule out a certain calendar effect in some variables such as mortality.

In conclusion, we identified significant differences between patients with hematological malignancies and solid tumors with PA BSI that should be considered when approaching cancer patients with suspected PA infection. Among the risk factors associated with overall mortality, IEAT and the administration of G-CSF were the only modifiable variables.

**Author Contributions:** Conceptualization, C.G.; methodology, C.R.-C., C.G.; software, J.C.; validation, C.R.-C., J.L.-A., M.P. (Marta Peña), I.R.-C., P.P.-A., E.A., C.O., M.A., M.M. (Miguel Montejo), M.M. (Malgorzata Mikulska), P.M.-D., F.H., O.G., L.D., H.M.P.M., A.-S.B., E.G., B.I., W.V.K., Z.R.P.-B., G.M.d.I.C., M.M.M., S.S.K., O.R.S., S.C., I.M.-G., J.I.M., M.Z.R.G., P.H., R.A., M.P. (Marta Peña), J.L.d.P., I.Y., R.T., A.M., A.N., J.C., C.G.; formal analysis, C.R.-C., C.G.; investigation, C.R.-C., C.G.; resources, C.G.; data curation, C.R.-C., J.L.-A., M.P. (Marta Peña), I.R.-C., P.P.-A., E.A., C.O., M.A., M.M. (Miguel Montejo), M.M. (Malgorzata Mikulska), P.M.-D., F.H., O.G., L.D., H.M.P.M., A.-S.B., E.G., B.I., W.V.K., Z.R.P.-B., G.M.d.I.C., M.M.M., S.S.K., O.R.S., S.C., I.M.-G., J.I.M., M.Z.R.G., P.H., R.A., M.P. (Maddalena Peghin), J.L.d.P., I.Y., R.T., A.M., A.N., J.C., C.G.; writing—original draft preparation, C.R.-C.; writing—review and editing, C.G.; visualization, C.R.-C., J.L.-A., M.P. (Marta Peña), I.R.-C., P.P.-A., E.A., C.O., M.A., M.M. (Miguel Montejo), M.M. (Malgorzata Mikulska), P.M.-D., F.H., O.G., L.D., H.M.P.M., A.-S.B., E.G., B.I., W.V.K., Z.R.P.-B., G.M.d.I.C., M.M.M., S.S.K., O.R.S., S.C., I.M.-G., J.I.M., M.Z.R.G., P.H., R.A., M.P. (Maddalena Peghin), J.L.d.P., I.Y., R.T., A.M., A.N., J.C., C.G.; supervision, C.G.; project administration, C.G.; funding acquisition, C.G., J.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) (CB21/13/00009; CB21/13/00079; CB21/13/00054; CB21/13/00086), Madrid, Spain.

**Institutional Review Board Statement:** The study was approved by the Institutional Review Board at Bellvitge University Hospital (local reference number PR408/17) and by the local Research Ethics Committees at the participating centers. It was conducted in accordance with the guidelines of the Declaration of Helsinki.

**Informed Consent Statement:** The need for informed consent was waived by the Clinical Research Ethics Committee due to the retrospective design of the study.

**Data Availability Statement:** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments:** We thank the ESCMID Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES) and the ESCMID Study Group for Immunocompromised Hosts (ESGICH) for supporting the study. We thank the Centres de Recerca de Catalunya (CERCA) Program and Generalitat de Catalunya for the institutional support. We thank the Spanish Network for Research in Infectious Diseases and the Río Hortega program of the Instituto de Salud Carlos III for the financial support of pre-doctoral student J. Laporte-Amargós and A. Bergas.
Conflicts of Interest: FH received speaker’s fees from Merck and Pfizer and research and educational grants from Pfizer. SSK receives honoraria from Pfizer, Merck, Gilead, and Menarini for speaker bureau and advisory boards. CG received speaker’s fees from MSD, Pfizer, and Gilead and research and grants from Pfizer and Merck. All the other authors declare no conflict of interests.

Appendix A

Ironic Study Investigators: Alba Bergas and Enric Sastre, Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, Barcelona, Spain. Marisol Rodríguez Arias, Oncology Department, Institut Català d’Oncologia (ICO)—Hospital Duran i Reynals, IDIBELL, Barcelona, Spain. Juan Aguilar-Company, Oncology Department, and Nieves Larrosa, Microbiology Department, Vall d’Hebron University Hospital, Barcelona, Spain. Celia Cardozo and Carolina García-Vidal, Infectious Diseases Department, Hospital Clínic i Provincial, Barcelona, Spain. Ibrahim Karim-Yaqub, Instituto do Câncer de Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo, Brazil. Raffaella Greco, Hematology and Bone Marrow Transplantation Unit, and Paola Cichero, Microbiology and Virology Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy. Caglayan Merve Ayaz, Infectious Diseases Department, Hacettepe University School of Medicine, Ankara, Turkey. Roberto Céspedes, Hematology Department, and Leire López-Soria, Microbiology Department, Cruces University Hospital, Bilbao, Spain. Laura Magnasco, Division of Infectious Diseases, University of Genoa (DISSAL) and Ospedale Policlinico San Martino, Genoa, Italy. Jesús Fortún, Infectious Diseases Department, Ramón y Cajal Hospital, Madrid, Spain. Diego Torres, Infectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina. Anna Boté, Infectious Diseases Department, and Mateu Espasa, Microbiology Department, Parc Taulí University Hospital, Sabadell, Barcelona, Spain. Mia Hold Montaguti, Infectious Diseases Department, Hospital Erasto Gaertner, Curitiba, Brazil. Pierre-Yves Bochud, Infectious Diseases Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Salvador Tabares Carrasco and Josefina Serrano López, Hematology Department, Reina Sofia University Hospital-IMIBIC-UCO, Córdoba. Hartmut Bertz, Hematology-Oncology Department, and Siegbert Rieg, Division of Infectious Diseases, Department of Medicine II, University of Freiburg Medical Center and Faculty of Medicine, Freiburg, Germany. Marina de Cueto, Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospitals Virgen Macarena and Virgen del Rocío—IBiS; Department of Medicine, University of Seville, Seville, Spain. José María Aguado, Infectious Diseases Unit, 12 de Octubre University Hospital, Madrid Spain. Juan Pablo Horcajada, Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, Barcelona, Spain. Saeed El Zein and Jean-François Jabbour, Infectious Diseases Division, American University of Beirut Medical Center, Beirut, Lebanon. Ayse Uyan-Onal Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir Turkey. Arzu Nazlı-Zeka Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylül University Faculty of Medicine, Izmir Turkey. Begoña Palop, Microbiology Department, Hospital Regional de Málaga, Málaga, Spain. Lina Clemencia Correa, Clínica Maraya, Pereira, Colombia. Amanda Aparecida da Silva Machado and Vitória Pinça Ruggi Dutra, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. Georg Maschmeyer, Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charité University Medical School, Berlin, Germany. Jose Munita, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago de Chile, Chile, and Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R). Matteo Bassetti and Nadia Castaldo, Infectious Diseases Clinic, University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy. Paloma Sangro del Alcázar, Internal Medicine Department, Navarra University Clinic, Pamplona, Spain.
21. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 2012, 18, 268–281. [CrossRef]

22. Klastresky, J.; Faems, M.; Rubenstein, E.B.; Boyer, M.; Elting, L.; Feld, R.; Gallagher, J.; Herrstedt, J.; Rapoport, B.; Rolston, K.; et al. The Multinational Association for Supportive Care in Cancer Risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J. Clin. Oncol.* 2000, 18, 3038–3051. [CrossRef]

23. Garner, J.S.; Jarvis, W.R.; Emori, T.G.; Horan, T.C.; Hughes, J.M. CDC definitions for nosocomial infections, 1988. *Am. J. Infect. Control* 1988, 16, 128–140. [CrossRef]

24. Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C.; Machado, F.R.; McIntyre, L.; Ostermann, M.; et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock. *Intensive Care Med.* 2021, 47, 1181–1247. [CrossRef]

25. Lanoix, J.P.; Schmit, J.L.; Douadi, Y. Bacterial lung sepsis in patients with febrile neutropenia. *Curr. Opin. Pulm. Med.* 2012, 18, 175–180. [CrossRef]

26. Braun, E.; Hussein, K.; Geffen, Y.; Rabino, G.; Bar-Lavie, Y.; Paul, M. Predominance of Gram-negative bacilli among patients with catheter-related bloodstream infections. *Clin. Microbiol. Infect.* 2014, 20, O627–O629. [CrossRef]

27. Gonçalves, P.; Menezes, F.G.; Tioliolo, A.R.; Silva, C.V.; Cardoso, M.F.S.; Santos, C.M.; Castagna, H.M.F.; Martino, M.D.V.; Correa, L. Secular trends in central line-associated bloodstream infection: Microbiological patterns of pathogens after preventive measures. *Infect. Control Hosp. Epidemiol.* 2015, 36, 1106–1107. [CrossRef]

28. Ripa, M.; Morata, L.; Rodríguez-Núñez, O.; Cardozo, C.; Puerta-Alcalde, P.; Hernández-Meneses, M.; Ambrosioni, J.; Linares, L.; Bodro, M.; Valcárcel, A.; et al. Short-term peripheral venous catheter-related bloodstream infections: Evidence for increasing prevalence of Gram-negative microorganisms from a 25-year prospective observational study. *Antimicrob. Agents Chemother.* 2018, 62, e00892-e18. [CrossRef]

29. Cordonnier, C., Tubau, F., Calatayud, L., Garcia-Vidal, C., Cisnal, M., Sanchez-Ortega, I., Duarte, R., Calvo, M., Carratala, J. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: Risk factors, antibiotic therapy and outcomes. *J. Antimicrob. Chemother.* 2011, 66, 657–663. [CrossRef]

30. Satlin, M.J.; Chen, L.; Douglass, C.; Hovan, M.; Davidson, E.; Soave, R.; La Spina, M.; Chassy, K.; Mayer, S.; et al. Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients. *Clin. Infect. Dis.* 2021, 73, 1257–1265. [CrossRef] [PubMed]

31. Mikulska, M.; Cordonnier, C. Fluoroquinolone prophylaxis during neutropenia: What can we expect nowadays? *Clin. Microbiol. Infect.* 2018, 24, 678–679. [CrossRef] [PubMed]

32. Albasanz-Puig, A.; Gudiol, C.; Puerta-Alcalde, P.; Ayaz, C.M.; Machado, M.; Hernandez-Cruz, A.; Akova, M.; et al. Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for Gram-negative bloodstream infections in hematological neutropenic patients: A propensity-matched cohort study (AMINOLACTAM Study). *Antimicrob. Agents Chemother.* 2021, 65, e004521. [CrossRef]

33. Albasanz-Puig, A.; Durá-Miralles, X.; Laporte-Amargós, J.; Mussetti, A.; Ruiz-Camps, I.; Puerta-Alcalde, P.; Abdala, E.; Oltolini, C.; Akova, M.; Montejo, J.M.; et al. Effect of combination antibiotic empirical therapy on mortality in neutropenic cancer patients with Pseudomonas aeruginosa pneumonia. *Microorganisms* 2022, 10, 733.

34. Bergas, A.; Albasanz-Puig, A.; Fernández-Cruz, A.; Machado, M.; Novo, A.; van Duijn, D.; Garcia-Vidal, C.; Hakki, M.; Ruiz-Camps, I.; Del Pozo, J.L.; et al. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to *Pseudomonas aeruginosa* in Neutropenic Hematologic Patients: A Matched Control Study (ZENITH Study). *Microbiol. Spectr.* 2022, 10, e0229221. [CrossRef]

35. Cordonnier, C.; Àlvarez, J.; Fernández-Meneses, M.; Ambrosioni, J.; Linares, L.; Cardozo, C.; Puerta-Alcalde, P.; Abdala, E.; Oltolini, C.; Akova, M.; Montejo, J.M.; et al. Effect of combination antibiotic empirical therapy on mortality in neutropenic cancer patients with Pseudomonas aeruginosa pneumonia. *Microorganisms* 2022, 10, 733.

36. Criscuolo, M.; Trecarichi, E.M. Ceftazidime/avibactam and ceftolozane/tazobactam for multidrug-resistant gram negatives in patients with hematologic malignancies: Current experiences. *Antibiotics* 2020, 9, 58. [CrossRef]

37. Chaftari, A.M.; Hachem, R.; Malek, A.E.; Mulasov, V.E.; Szvalb, A.D.; Jiang, Y.; Yuan, Y.; Ali, S.; Deeba, R.; Chaftari, P.; et al. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients with Hematological Malignancies. *Open Forum. Infect. Dis.* 2022, 9, ofac079. [CrossRef]